UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lessons Learned: Dose Selection of Small Molecule-Targeted Oncology Drugs

Clinical cancer research, 2016-06, Vol.22 (11), p.2630-2638

2016

Volltextzugriff (PDF)

Barriers to adherence to oral drug regimens in oncology and strategies for improvement

Clinical advances in hematology & oncology, 2022-02, Vol.20 (2), p.75

Bullock, Julie M

2022

Volltextzugriff (PDF)

Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk‐Benefit Approach

Journal of clinical pharmacology, 2017-10, Vol.57 (S10), p.S105-S115

2017

Volltextzugriff (PDF)

Population pharmacokinetics and exposure–response of trilaciclib in extensive‐stage small cell lung cancer and triple‐negative breast cancer

British journal of clinical pharmacology, 2023-03, Vol.89 (3), p.1067-1079

2023

Volltextzugriff (PDF)

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

Clinical cancer research, 2013-09, Vol.19 (17), p.4559-4563

2013

Volltextzugriff (PDF)

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

Clinical cancer research, 2012-11, Vol.18 (21), p.5845-5849

2012

Volltextzugriff (PDF)

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

Clinical cancer research, 2008-01, Vol.14 (2), p.352-359

2008

Volltextzugriff (PDF)

Pediatric oncology drug development and dosage optimization

Frontiers in oncology, 2024-01, Vol.13, p.1235947-1235947

2024

Volltextzugriff (PDF)

U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia

The oncologist (Dayton, Ohio), 2014-01, Vol.19 (1), p.94-99

2014

Volltextzugriff (PDF)

Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice

Biopharmaceutics & drug disposition, 2012-03, Vol.33 (2), p.99-110

2012

Volltextzugriff (PDF)

The Influence of St. John's Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate

Pharmacotherapy, 2004-11, Vol.24 (11), p.1508-1514

2004

Volltextzugriff (PDF)

Evaluation of the Cardiac Safety of Long‐Acting Endectocide Moxidectin in a Randomized Concentration‐QT Study

Clinical and translational science, 2018-11, Vol.11 (6), p.582-589

2018

Volltextzugriff (PDF)

Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT

Journal of clinical pharmacology, 2007-05, Vol.47 (5), p.633-641

2007

Volltextzugriff (PDF)

Ixabepilone in Combination with Capecitabine and as Monotherapy for Treatment of Advanced Breast Cancer Refractory to Previous Chemotherapies

Clinical cancer research, 2008-07, Vol.14 (14), p.4378-4384

2008

Volltextzugriff (PDF)

Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype Typhi

Antimicrobial Agents and Chemotherapy, 2005-05, Vol.49 (5), p.1775-1781

2005

Volltextzugriff (PDF)

Induction of imatinib metabolism by hypericum perforatum

Blood, 2004-08, Vol.104 (4), p.1229-1230

2004

Volltextzugriff (PDF)

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Clinical cancer research, 2015-06, Vol.21 (12), p.2666-2670

2015

Volltextzugriff (PDF)

Leveraging Modeling Simulation in Oncology: How the use of MS in cancer trials from the outset can help address those critical "what if?" scenarios and accelerate oncology drug development

Applied clinical trials, 2018-09, Vol.27 (9), p.22

2018

Volltextzugriff (PDF)

Leveraging Modeling & Simulation in Oncology

Applied clinical trials, 2018-09, Vol.27 (9), p.22-24

2018

Volltextzugriff (PDF)

FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma

Clinical cancer research, 2015-04, Vol.21 (7), p.1525-1529

2015

Volltextzugriff (PDF)

FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease

Clinical cancer research, 2015-03, Vol.21 (5), p.950-954

2015

Volltextzugriff (PDF)

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

Clinical cancer research, 2015-08, Vol.21 (16), p.3586-3590

2015

Volltextzugriff (PDF)

Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation

Therapeutic drug monitoring, 2006-02, Vol.28 (1), p.62-66

2006

Volltextzugriff (PDF)

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis

Clinical cancer research, 2012-06, Vol.18 (12), p.3212-3217

2012

Volltextzugriff (PDF)

Effect of Tenofovir Disoproxil Fumarate on the Pharmacokinetics and Pharmacodynamics of Total, R-, and S-Methadone

Pharmacotherapy, 2004-08, Vol.24 (8), p.970-977

2004

Volltextzugriff (PDF)

1 – 25 von 120

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(102)
Mit Volltextzugriff
(90)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(120)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Science & Technology
(66)
Life Sciences & Biomedicine
(60)
Humans
(51)
Female
(24)
Male
(19)
Oncology
(19)
Biological And Medical Sciences
(16)
Middle Aged
(16)
Adult
(13)
Aged
(13)
Medical Sciences
(13)
United States
(12)
Animals
(10)
Pharmacology & Pharmacy
(10)
Drug Approval
(9)
United States Food And Drug Administration
(9)
Antineoplastic Agents
(8)
Pharmacology. Drug Treatments
(8)
Social Sciences
(7)
Adolescent
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Lessons Learned: Dose Selection of Small Molecule-Targeted Oncology Drugs

Barriers to adherence to oral drug regimens in oncology and strategies for improvement

Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk‐Benefit Approach

Population pharmacokinetics and exposure–response of trilaciclib in extensive‐stage small cell lung cancer and triple‐negative breast cancer

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

Pediatric oncology drug development and dosage optimization

U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia

Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice

The Influence of St. John's Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate

Evaluation of the Cardiac Safety of Long‐Acting Endectocide Moxidectin in a Randomized Concentration‐QT Study

Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT

Ixabepilone in Combination with Capecitabine and as Monotherapy for Treatment of Advanced Breast Cancer Refractory to Previous Chemotherapies

Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype Typhi

Induction of imatinib metabolism by hypericum perforatum

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Leveraging Modeling Simulation in Oncology: How the use of MS in cancer trials from the outset can help address those critical "what if?" scenarios and accelerate oncology drug development

Leveraging Modeling & Simulation in Oncology

FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma

FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis

Effect of Tenofovir Disoproxil Fumarate on the Pharmacokinetics and Pharmacodynamics of Total, R-, and S-Methadone

Suchergebnisse filtern